

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Johannes Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
David Pisetsky

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.384

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Nova Techset Private Limited, Bengaluru & Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 1581** Bias? Not so fast
J M Kremer

Recommendation

- 1583** EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
M Yates, R A Watts, I M Bajema, M C Cid, B Crestani, T Hauser, B Hellmich, J U Holle, M Laudien, M A Little, R A Luqmani, A Mahr, P A Merkel, J Mills, J Mooney, M Segelmark, V Tesar, K Westman, A Vaglio, N Yalçındağ, D R Jayne, C Mukhtyar

Clinical and epidemiological research

- 1595** Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review
J Durán, M Bockorny, D Dalal, M LaValley, D T Felson
- 1599** Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis
K E Linnner, A Patwardhan, L G Rider, R Abdul-Aziz, Y L Wu, E Lundström, L Padyukov, B Zhou, A Alhomosh, D Newsom, P White, K B Jones, T P O'Hanlon, F W Miller, C H Spencer, C Y Yu
- 1607** Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium
D Hunter, M Nevitt, J Lynch, V B Kraus, J N Katz, J E Collins, M Bowes, A Guermazi, F W Roemer, E Losina, for the FNIH OA Biomarkers Consortium
- 1615** Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
K Franklyn, C S Lau, S V Navarra, W Louthrenoo, A Lateef, L Hamijoyo, C S Wahono, S L Chen, O Jin, S Morton, A Hoi, M Huq, M Nikpour, E F Morand, for the Asia-Pacific Lupus Collaboration
- 1622** Autoimmune diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS)
A S Holmqvist, J H Olsen, L Mellemejaer, S Garvick, L Hjorth, C Moëll, B Månsson, L Tryggvadottir, H Hasle, J F Winther, on behalf of the ALiCCS study group
- 1630** Clinical significance of worsening versus stable preradiographic MRI lesions in a cohort study of persons at higher risk for knee osteoarthritis
L Sharma, M Nevitt, M Hochberg, A Guermazi, F W Roemer, M Crema, C Eaton, R Jackson, K Kwok, J Cauley, O Almagor, J S Chmiel

- 1637** Prediction of disease relapses by multi-biomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
J Rech, A J Hueber, S Finzel, M Englbrecht, J Haschka, B Manger, A Kleyer, M Reiser, J F Cobra, C Figueiredo, H-P Tony, S Kleinert, J Wendler, F Schuch, M Ronneberger, M Feuchtenberger, M Fleck, K Manger, W Ochs, M Schmitt-Haendle, H-M Lorenz, H Nuesslein, R Alten, J Henes, K Krueger, G Schett

- 1645** Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)
K Horslev-Petersen, M L Heitland, L M Ørnbjerg, P Junker, J Pødenphant, T Ellingsen, P Ahlquist, H Lindegaard, A Linauskas, A Schlemmer, M Y Dam, I Hansen, T Lottenburger, C G Ammitzbøll, A Jørgensen, S B Krintel, J Raun, J S Johansen, M Østergaard, K Stengaard-Pedersen, OPERA Study-Group

- 1654** Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
S Yokota, Y Itoh, T Morio, H Origasa, N Sumitomo, M Tomobe, K Tanaka, S Minota

- 1661** Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort
C Desthieux, A Molto, B Granger, A Saraux, B Fautrel, L Gossec

- 1667** Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
A Richter, J Listing, M Schneider, T Klopsch, A Kapelle, J Kaufmann, A Zink, A Strangfeld

- 1674** Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims
D H Solomon, C-C Liu, I-Hsin Kuo, A Zak, S C Kim

- 1680** Incidence and predictors for cardiovascular events in patients with psoriatic arthritis
L Eder, Y Wu, V Chandran, R Cook, D D Gladman

- 1687** Genetic variants in ANCA-associated vasculitis: a meta-analysis
C Rahmatulla, A L Mooyaar, D van Hooven, J W Schoones, J A Bruijn, O M Dekkers, European Vasculitis Genetics Consortium, I M Bajema

- 1693** Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
M B Ruiz-Arquello, A Maguregui, A R del Agua, D Pascual-Salcedo, A Martínez-Feito, T Jurado, C Plasencia, A Balsa, F Linares-Tello, J Rosas, N Torres, A Martínez, D Nagore

Basic and translational research

- 1697** IL-22 capacitates dermal fibroblast responses to TNF in scleroderma
N C Brembilla, A M Dufour, M Alvarez, S Hugues, E Montanari, M-E Truchetet, P Lonati, L Fontao, A Gabrielli, S Vettori, G Valentini, W-H Boehncke, P Meroni, C Chizzolini

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

COPE

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it



The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 1706** Netrin-1 is highly expressed and required in inflammatory infiltrates in wear particle-induced osteolysis

A Mediero, B Ramkhelawon, T Wilder, P E Purdue, S R Goldring, M Z Dewan, C Loomis, K J Moore, B N Cronstein

- 1714** Halofuginone attenuates osteoarthritis by inhibition of TGF- β activity and H-type vessel formation in subchondral bone



OPEN ACCESS

Z Cui, J Crane, H Xie, X Jin, G Zhen, C Li, L Xie, L Wang, Q Bian, T Qiu, M Wan, M Xie, S Ding, B Yu, X Cao

- 1722** Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis

G Reynisdottir, H Olsen, V Joshua, M Engström, H Forslund, R Karimi, C M Sköld, S Nyren, A Eklund, J Grunewald, A I Catrina

- 1728** Activated T cells enhance interferon- α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes

D Leonard, M-L Eloranta, N Hagberg, O Berggren, K Tandre, G Alm, L Rönnblom

Letters

- 1735** High soluble IL-7 receptor expression in Sjögren's syndrome identifies patients with increased immunopathology and dryness

M R Hillen, S L M Blokeland, A P Risselada, A Bieker, B R Lauwerys, A A Kruize, T R D J Radstake, J A G van Roon

- 1736** Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort



OPEN ACCESS

Y Allanore, C P Denton, T Krieg, P Cornelisse, D Rosenberg, B Schwierin, M Matucci-Cerinic, on behalf of the DUO Investigators

Electronic pages

Correspondence

- e57** Paracetamol: a probably still safe drug

A Battaglia, P L Aprile, I Cricelli, D Fomasani, A Fanelli, C Cricelli, F Lapi

- e58** Biological agents for giant cell arteritis: treat to target

S Moiseev, P Novikov, A Meshkov, I Smitienko

- e59** Response to: 'Biologic agents for giant cell arteritis: treat to target' by Moiseev *et al*

R Conway, E S Molloy

- e60** 'Lower anti-drug antibodies with etanercept biosimilar: can C_{trough} explain the differences?'

C A Shah

- e61** Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can C_{trough} explain the differences' by Shah

P Emery, J Vencovský, J Ghil, J W Kang